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18F-Sodium Fluoride
Positron Emission Tomography
An In Vivo Window Into Coronary
Atherosclerotic Plaque Biology*
Richard T. George, MD
Baltimore, Maryland
Coronary atherosclerosis is a progressive disease that in-
volves vascular inflammation, development of cholesterol
burdened atheroma, mechanisms of injury and repair, and
subsequent calcification (1). Coronary artery calcification
(CAC) detected with cardiac computed tomography has
been shown to correlate well with overall plaque burden and
is an independent predictor of cardiovascular events (2,3). It
is well known that traditional cardiovascular risk factors
contribute to the first incidence of CAC and CAC progres-
sion (4,5). Once present, CAC is diagnostic of the presence
of coronary atherosclerosis, with increasing CAC burden
correlating with increasing atherosclerosis burden and in-
ferring different risks for cardiovascular events dependent on
age, sex, race, and ethnicity (6). Once CAC is present, the
atherosclerotic disease process is firmly established and
therapies to induce plaque progression, although effective,
are modest at best and inevitably leave a substantial residual
risk of coronary events (7).
See page 1539
In this issue of the Journal, Dweck et al. (8) report an
ntriguing study that uses 18F sodium fluoride (18F-NaF)
nd 18F fluorodeoxyglocose (18F-FDG) positron emission
omography (PET) in a study aimed to examine the
easibility of performing noninvasive imaging of active
alcification and inflammation. The study highlights some
f the difficulties in performing inflammation imaging with
8F-FDG in the coronary arteries, due to the avid uptake of
8F-FDG by the myocardium, but at the same time
emonstrates a promising technique to measure active
alcification of the coronary arteries in vivo. Several findings
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Medical Imaging.from this study are suggestive of the potential of 18F-NaF
for studying atherosclerotic plaque biology in vivo. The
authors demonstrated that patients with abnormal 18F-NaF
imaging were more likely to have a history of coronary artery
disease, revascularization, and angina. In addition, 18F-
NaF uptake correlated with Framingham risk scores used
for the prediction of coronary heart disease events. There
was also a good correlation with CAC score, but CAC and
18F-NaF uptake were not always synonymous. Forty-one
percent of patients with a CAC score1,000 demonstrated
no significant 18F-NaF uptake, and some patients with
minimal calcium had increased 18F-NaF uptake. At the
present time, the significance of severe calcification in the
absence of 18F-NaF uptake is not known. One can hypoth-
esize that 18F-NaF uptake in areas of noncalcified or
minimally calcified plaque might represent areas of active
calcification. This hypothesis, if true, has significant clinical
implications, because there is evidence that coronary calci-
fication is a result of plaque rupture and is part of the
healing process (9), and patients with cardiac events are
more likely to have CAC progression (10,11).
Coronary artery calcification is a dynamic process that
resembles bone formation. It has been demonstrated that
calcification involves osteoblast-like cells as well as some of
the same cytokines, transcription factors, and bone morpho-
genetic proteins that are involved in bone formation and
remodeling (12,13). Large epidemiologic studies suggest a
strong association between factors that promote bone loss
and atherosclerotic progression (14). 18F-NaF has been
recognized as an excellent radiopharmaceutical for imaging
pathological processes involving bone formation and re-
modeling, including primary bone malignancies, metastatic
disease, and Paget’s disease. 18F-NaF is relatively easy to
produce with beam currents achievable in today’s clinical
cyclotrons. Hydroxyapatite, a constituent of bone and sim-
ilarly calcified atherosclerotic plaque, is capable of exchang-
ing hydroxyl groups with the fluoride ion (15). Although
noncontrast computed tomography can detect the presence
of coronary calcification, it cannot detect active calcification.
18F-NaF PET might provide this opportunity.
There are several limitations of the current study that
require mentioning. First, this study is a substudy. The
patient population was initially enrolled to study inflamma-
tion and active calcification in patients with aortic sclerosis
or stenosis (16). Therefore, the population studied is not
ideal for making final conclusions with regard to the efficacy
of this technique in patients at risk of developing coronary
atherosclerosis and cardiovascular events. Second, there is
no histopathology confirmation of what 18F-NaF uptake
indicates. Although the authors postulate 18F-NaF uptake
or absence thereof differentiates between active and dormant
calcification, this cannot be confirmed. This conclusion can
only be derived from a study that includes histopathology or
from a study that examines whether the presence of 18F-
NaF uptake correlates with the appearance of new calcified
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authors used noncontrast CAC scoring images to detect
calcified plaque. It is unknown whether areas of tracer
uptake in the absence of calcification were areas of noncal-
cified plaque or areas with spotty calcification, too small to
be detected by CAC imaging alone. Although the study
tries to make comparisons with Framingham Risk Scores,
there is no follow-up of events, and the predictive ability of
18F-NaF PET cannot be confirmed.
The authors should be congratulated, regardless of these
limitations, on taking the first step in demonstrating the
feasibility of 18F-NaF PET imaging of the coronary arter-
ies. This technique shows great promise in the noninvasive
study of biological processes that contribute to coronary
atherosclerosis. In addition, with further validation, it might
be an early marker of plaque progression that could be used
to guide clinical trials of novel therapeutics aimed at plaque
regression and reducing cardiovascular events.
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